+Vote!
The Materials Chemists (Free subscription) | 08/10/2008
Let me tell you this anecdote: The 2008 Prize for chemistry brings to mind an Innocentive Challenge , to find a biomarker, for Charcot’s Disease – a still incurable type of sclerosis. This challenge, by the way, is still open to the end of the current year, from memory, and is now supported by the Rockefeller Foundation. I echoed this at the time; for the importance of the subject and the equivalent...
+Vote!
Bellaonline.com (Free subscription) | 08/10/2008
Tuberous sclerosis complex (TSC) causes amongst many symptoms those of some learning disabilities.
+Vote!
Daily Intelligencer - New York Magazine (Free subscription) | 06/10/2008
Photo: Getty Images On October 7, Ben Stiller returns to town as the "host and creative director" of the Project ALS gala at the Waldorf=Astoria; it's a benefit for amyotrophic lateral sclerosis, the degenerative neurological disease that befell his friend Jennifer Estess, with whom he co-founded downtown theater group Naked Angels in the early eighties. "With all the other causes out there in the...
+Vote!
Beale Street Beat (Free subscription) | 02/10/2008
Former Raven and Baltimore Stallion linebacker O.J. Brigance was a true warrior on the playing field, but now he’s in a battle like none other he’s ever experienced. This time the opponent isn’t a hulking fullback, or tailback, but a much stronger enemy, amyotrophic lateral sclerosis (ALS). But just as he gave his all on the [...]
+Vote!
On The record Magazine (Free subscription) | 01/10/2008
NBA star Alonzo Mourning can now add author to his resume following Tuesday’s release of his book “Resilience,” a 231-page account of his life story, including his battle with the life-threatening kidney disease, focal segmental glomerular sclerosis. The athlete said he was encouraged to share his life story after following the resilience of cyclist Lance [...]
+Vote!
A Georgia Lawyer (Free subscription) | 30/09/2008
From the FDA site: A U.S. Food and Drug Administration's analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as "Lou Gehrig's Disease." The analysis was reported on Monday, Sept. 29, 2008 in Pharmacoepidemiology and Drug Safety. "The FDA's review, which began in 2007, is an example of...
+Vote!
FDA MedWatch (Free subscription) | 30/09/2008
New analysis of 41 long-term controlled clinical trials provides evidence that use of statins does not increase incidence of ALS.
+Vote!
Pharmalot (Free subscription) | 29/09/2008
This is according to an agency analysis, which began last year and was undertaken after FDA officials received a higher-than-expected number of adverse event reports of amyotrophic lateral sclerosis, or ALS, in patients taking statins. Nonetheless, the FDA says further study is warranted. The review of data from 41 long-term controlled clinical trials showed no increased [...]
+Vote!
Food and Drug Administration (Free subscription) | 29/09/2008
A U.S. Food and Drug Administration's analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as Lou Gehrig's Disease.
+Vote!
FRC Blog (Free subscription) | 28/09/2008
Adult stem cells have been used in a rat model of ALS (amyotrophic lateral sclerosis; "Lou Gehrig's disease") to strengthen muscles and their connecting nerves . Researchers injected bone marrow adult stem cells carrying a gene for GDNF (glial cell line-derived neurotrophic factor), a nurturing protein for nerves. Previous work by the group had shown that transplanting neural stem cells that released...
+Vote!
Medical News Today (Free subscription) | 24/09/2008
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint. The primary objective of the study was to evaluate the efficacy of the new formulation of Rebif®, compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of...
+Vote!
Medical News Today (Free subscription) | 24/09/2008
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that patient enrollment has been completed in the REFLEX trial (REbif FLEXible dosing in early multiple sclerosis). This randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif® (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in...
+Vote!
Medical News Today (Free subscription) | 24/09/2008
Following Prime Minister Gordon Brown's speech today at the Labour party conference, the MS Society welcomes news of a commitment to end prescription charges for people with long-term conditions. Speaking at the conference in Manchester, Mr Gordon Brown said: "....so our plan is next year to abolish all prescription charges for everyone with cancer. And this is not the limit of our commitment to a...
+Vote!
medinnovationblog (Free subscription) | 24/09/2008
Oh, I pray I shall never come down, with hardening of the categories. Just thinking of it brings a frown. It’s worse than hardening of the arteries. It’s manifested by mental sclerosis, by absolute closemindedness, by absence of cerebral osmosis, by intellectual nearsightedness. It’s common among every computer geek, who thinks for everything there’s a protocol, for every problem an algorithm they...
+Vote!
The Earth Times Online Newspaper (Free subscription) | 23/09/2008
Cites Association between Military Service and Later Development of ALS WASHINGTON, Sept. 23 /PRNewswire-USNewswire/ -- Veterans with amyotrophic lateral sclerosis (ALS) may receive badly-needed support for themselves and their fa...
